The Vaccine Knowledge Project aims to be a source of independent information about vaccines and infectious diseases. We provide clear information on complex topics and back it up with references to high-quality research. All our content is aimed at the general public and designed to help people make informed decisions about vaccine issues. The content is also suitable for healthcare professionals such as health visitors, school nurses, general practitioners and paediatricians.
The Vaccine Knowledge Project is managed by Oxford Vaccine Group , an academic research group in the Department of Paediatrics at the University of Oxford. The site is updated regularly to make sure it is as accurate as possible, and overseen by academic staff at the cutting edge of vaccine research. All medical content is reviewed by Professor Andrew Pollard , Director of Oxford Vaccine Group.
The project is run independently by academic staff at the University of Oxford and does not receive any funding from pharmaceutical companies. The project receives funding from the NIHR Oxford Biomedical Research Centre (NIHR is funded by the Department of Health) and from the Oxford Martin School at the University of Oxford. However, the funders have no strategic or editorial role in the development of the website or its content. Professor Pollard is currently chair of the Joint Committee on Vaccination and Immunisation (JCVI) , an independent statutory body that advises the UK Department of Health on vaccination issues.
Since July 2016 the Vaccine Knowledge Project has been a member of the World Health Organization's Vaccine Safety Net . This means that this website has been judged to meet the World Health Organization's criteria for providing good quality information about vaccine safety issues.
This vaccine gives protection against measles, mumps and rubella (German measles), all of which can cause serious disease.
Since summer 2015 this vaccine has been given to teenagers and new university students in the UK. It protects against four types of meningococcal disease, which is a major cause of meningitis and septicaemia.
Information about the ingredients in vaccines used routinely in the UK (active ingredients, added ingredients and products used in vaccine manufacture).
In the UK the chickenpox vaccine is not currently part of the routine childhood schedule. It is recommended for those in close contact with people who are at risk of complications from chickenpox.
When a high percentage of the population is vaccinated, it is difficult for infectious disease to spread because there are not many people who can be infected. This is called ‘herd immunity’ and it gives protection to vulnerable people in the community.
This vaccine protects against five serious diseases: diphtheria, tetanus, whooping cough (pertussis), polio and Hib disease.
The MenB vaccine was introduced into the UK schedule in September 2015. This new vaccine was developed to protect against meningococcal disease type B, a major cause of meningitis and blood poisoning.